The importance of exosomal PDL1 in tumour immune evasion
Top Cited Papers
- 21 January 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Reviews Immunology
- Vol. 20 (4), 209-215
- https://doi.org/10.1038/s41577-019-0264-y
Abstract
The interaction of programmed cell death 1 ligand 1 (PDL1) with its receptor programmed cell death 1 (PD1) inhibits T cell responses, and blockade of this interaction has proven to be an effective immunotherapy for several different cancers. PDL1 can be expressed on the surface of tumour cells, immune cells and other cells in the tumour microenvironment but is also found in extracellular forms. Recent studies have explored the importance of different forms of extracellular PDL1, such as on exosomes or as a freely soluble protein, and have shown that PDL1-expressing exosomes can inhibit antitumour immune responses. In patients with melanoma, exosomal PDL1 is also a marker of immune activation early after initiation of therapy with PD1-blocking antibodies and predicts a clinical response to PD1 blockade. In this Progress article, we highlight recent insights into the role of exosomal PDL1 in immune oncology and how it may be useful as a biomarker for the management of cancer or to define a subset of patients who would benefit from therapeutics that block exosome production.Keywords
This publication has 69 references indexed in Scilit:
- Circulating Exosomal microRNAs as Biomarkers of Colon CancerPLOS ONE, 2014
- Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injuryStem Cell Research, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- Soluble B7-H1: Differences in production between dendritic cells and T cellsImmunology Letters, 2011
- Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell linesCytokine, 2011
- B7-H4 expression associates with cancer progression and predicts patient’s survival in human esophageal squamous cell carcinomaCancer Immunology, Immunotherapy, 2011
- Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell CarcinomaClinical Cancer Research, 2011
- B7‐1/2, but not PD‐L1/2 molecules, are required on IL‐10‐treated tolerogenic DC and DC‐derived exosomes for in vivo functionEuropean Journal of Immunology, 2009
- CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct MechanismsMolecular and Cellular Biology, 2005